MedTrace Logo

Paracetamol in Addition to WHO Step III Opioids in Chronic Cancer Pain Control

NCT05088876 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2026-04-13

No results posted yet for this study

Summary

Blinded withdrawal of regular co-medication with paracetamol in chronic pain patients under strong opioids on pain control.

Conditions

Interventions

DRUG

Placebo

Blinded withdrawal of regular co-medication with paracetamol

DRUG

Paracetamol

Paracetamol in the dose already used

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Evangelia Liakoni · Inselspital, Bern University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-28
Primary Completion
2026-03-05
Completion
2026-03-05

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05088876 on ClinicalTrials.gov